Related Experiment Video

Updated: Jun 16, 2026

Retinal Pathophysiological Evaluation in a Rat Model
09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope?

Sayeeda Rahman1, Aziz Al-Shafi Ismail, Abdul Rashid A Rahman

  • 1Department of Clinical Sciences, School of Life Sciences, University of Bradford, Bradford, UK.

International Journal of Diabetes in Developing Countries
|February 19, 2010
PubMed

Insights

This review explores how rosiglitazone and ramipril may prevent arterial damage in diabetes and impaired glucose tolerance. These medications show potential in managing diabetic macrovasculopathy and improving cardiovascular outcomes.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Cardiovascular diseases significantly increase morbidity and mortality in diabetic patients.
  • Diabetic macrovasculopathy involves arterial structural and functional changes, leading to endothelial dysfunction and arterial stiffness.
  • Managing diabetic complications requires strict glycemic control, healthy lifestyle, and pharmacological interventions.

Purpose of the Study:

  • To review the potential of rosiglitazone (a thiazolidinedione) and ramipril (an ACE inhibitor) in preventing preclinical macrovasculopathy.
  • To highlight their roles in managing patients with diabetes and impaired glucose tolerance (IGT).

Main Methods:

  • Literature review focusing on clinical trials and studies.
  • Analysis of the effects of rosiglitazone and ramipril on arterial health in diabetic and IGT populations.

Main Results:

  • Thiazolidinediones (TZDs) and Angiotensin Converting Enzyme (ACE) inhibitors have shown promise in clinical trials.
  • These drug classes may delay diabetes onset, facilitate regression of IGT to normoglycemia, and reduce cardiovascular events.

Conclusions:

  • Rosiglitazone and ramipril warrant further investigation for their protective roles against diabetic macrovasculopathy.
  • These agents could be crucial in managing cardiometabolic risk factors and improving long-term outcomes in at-risk populations.

Keywords:
Diabetic vasculopathyramiprilrosiglitazone

Related Concept Videos

Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...